univers coverag
calendar event
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
bottom line afternoon sni op announc restructur
agreement global develop commerci right
patisiran ttr amyloidosi follow-on drug turn sni obtain global
develop commerci right fitusiran hemophilia variou royalti includ
global sale owe either parti exchang view
deal posit offer full control enhanc strateg flexibl
prepar launch patisiran later year one key question prior announc
whether would abl develop follow-on product way
jeopard patisiran concern base prior alny/sni deal term compani
split franchis new term agreement retain global
product sale depend tier royalti owe sni deal definit help
solv prior conflict-of-interest extent previous want cannib patisiran
howev commerci set-up still bit complic alnylam patisiran remain much
profit two product confer call put forth variou way may develop
ttrsc could offer meaning upsid model success howev either scenario
still anticip potenti subcutan inject would like take share away
patisiran thu remain point interest compani strategi evolv convers
give full fitusiran right rel royalti owe sale small price pay opinion
given program clinic risk broader competit risk associ impact program
rather crowd hemophilia space
new term put fulli driver seat ttr return hemophilia though compani
retain claim tier royalti
view restructur deal offer posit intang via tighter focu control
ttr franchis
sni one global licens pick left collabor agreement lumasiran like next
product decis
averag method dcf price earn price sale
bottom line yesterday even celgen announc come agreement
acquir impact biomedicin develop inhibitor fedratinib up-front futur
mileston payment could reach add-on indic certain sale threshold
investor anticip meaning acquisit celgen may
first sever extern busi develop deal compani year acquisit
impact center around fedratinib inhibitor complet phase develop
myelofibrosi mf prior put clinic hold fda case seriou
neurolog advers event call wernick encephalopathi impact abl re-acquir fedratinib
sanofi august fda lift clinic hold follow thorough retrospect
analysi clear drug associ celgen believ file nda approv
myelofibrosi suggest approv like least us indic
see commerci opportun fedratinib limit sever reason discontinu
fedratinib trial sever limit dataset celgen present regul
physician alik make difficult celgen compet first-to-market jak inhibitor
jakafi ruxolitinib indic viabl strategi one celgen like pursu
captur sub-popul jakafi refractori intoler patient could
individu mf fedratinib phase ii data suggest drug strong efficaci believ
commerci opportun fedratinib rang perhap much
less peak revenu potenti assign incy/op jakafi celgen seem less
incentiv pursu addit indic beyond myelofibrosi fedratinib sinc would result
substanti expens drug limit patent durat commerci potenti subject
celgen burdensom development mileston payment could make deal less econom
tax reform resurg retail volum visibl pt
bottom line follow guidanc call last week thorough review
increas pt posit stock given better
visibl earn signific rebound retail volum approxim
earn benefit tax reform deal aet mp like go
lengthi review process doj believ chanc deal
ultim approv instrument drive drug price red oak
jv pbm solut increas pt maintain op rate
parti sound interest believ still leverag
may leverag mani believ
termin fee payabl doj block
adjust ep exclud acquisit amort one-tim item exclud interest expens relat
aet transact exclud revenu earn aet deal
bottom line jan file -aet merger point aet mp op
discuss parti support previous publish view manag
care vantag point mp like buyer new vertic combin
 wcg like target esrx mp could buyer seller ci may get pressur make
deal decis chang control file wcg oct
view parti cite discuss aet possibl combin
though end possibl mid oct like esrx parti also discuss aet
possibl combin joint retail health clinic pilot co-brand medicar product
like view given ownership retail clinic also possibl though much
lower likelihood own clinic three state termin fee
parti liabl standard ground merger agreement expir dec could
extend month mutual consent valuat conduct advisor standard
sector compar multipl compar transact dcf methodolog lazard advis
aet per share barclay goldman sach wider rang lower mid point
aet deal price compani financi statement point conserv earn growth outlook
aet consensu like motiv deal though modestli bullish top-lin view
surprisingli bullish view earn forecast aet
though pro-forma consolid earn lower street despit synergi mm year post
close final mr bertolini two aet board member join board
enter employ compens arrang aet execut offic includ
presid karen lynch cfo shawn guertin may pose execut risk view
cvs-aet file proxi file propos merger januari pleas see
point like less like parti view parti also discuss
aet time talk
parti discuss aet like esrx view though decid merg
aet oct esrx view could buyer seller
expect could pressur ci op acceler decis make possibl horizont
combin wcg ci deal wcg could low double-digit accret year
post close given synergi horizont natur transact
aet subject termin fee either parti breach termin
initi deadlin decemb extens mutual consent
date none aet execut offic includ cfo shawn guertin presid
karen lynch enter agreement affili regard employ
compens arrang surviv corpor creat execut integr
risk view
aet less bullish earn outlook street though modestli bullish top-
line medium term
view estim larg line consensu estim
combin compani earn project weaker street estim individu compani
valuat conduct advisor standard sector compar multipl compar
transact dcf methodolog lazard advis aet per share barclay goldman
sach advis wider rang lower mid point appropri aet deal price
preannouc highlight strong revenu cologuard momentum
bottom line remain outperform rate given view cologuard remain highli
under-penetrated market estim strong believ
could deliv penetr revenu long-term penetr
sale today pre-announce result afternoon come midpoint
ahead street revenu estim driver beat cologuard
asp per test quarter vs street estim cologuard test complet
quarter essenti in-lin vs street us recommend buy
stock question around test given holiday punctuat quarter test within
full-year guid rang moreov cologuard remain highli under-penetrated
long-term goal reach penetr add quarter bring
total penetr believ reflect effort larg hospit system
asp drove upsid test volum in-lin
number lever pull drive upsid
cologuard sale ramp remain under-appreci re-ord rate signific room
improv level view
hospit provid like favor cologuard order improv perform measur
hedi rate
rais estim price target anoth impress ingrezza
 methodolog dcf analysi termin growth rate discount rate
bottom line afternoon pre-announc outstand includ
ingrezza sale versu consensu estim result rais
product sale estim -- solid print even impress per
math consid fact price per script drop sequenti compani work
convert patient capsul three strong quarter surpass
consensu estim continu earli trajectori launch remain support
larg tardiv dyskinesia market opportun turn increas sale project
price target estim script written versu written
indic work convert franchis toward capsul price per
script drop reduct expect price continu repres
headwind model sequenti drop upon addit realiz convers
steadi price thereaft impress print underli view current ingrezza
consensu far low increas revenu estim along
impli margin expans new price target also expect profit
basi also announc retir longtim discuss
ingrezza sale beat sell side consensu impress broadli even context
recent stock run
look anoth excit year three potenti clinic readout
also announc retir chief medic offic appoint new
strong credenti stock trade announc view buy opportun
revenu mm ep
rosmantuzumab fail ceo new endeavor futur remain
bottom line histor cautiou ome prospect cancer stem cell
csc -focus pipelin product candid includ partnership celg op gsk mp
bayer follow disclosur sever fail trial last week ome announc
ceo paul hast resign pursu new career opportun also provid multipl pipelin
updat includ disappoint rosmantuzumab phase clinic data fail
provid compel evid clinic benefit ome focus effort io asset anti-tigit
celg partner proprietari gitrl-fc phase well
csc asset navicixizumab bispecif partner celg think ome continu
remain show-m stori believ could take time investor re-engag
meaning way ome disclos end cash suffici run oper
ceo paul hast resign pursu new career opportun effect januari
anti-tigit celg partner program track
navicixizumab bispecif partner celg studi on-going interim data
least one studi expect
bottom line ultragenyx report posit interim top-line gene therapi
ornithin transcarbamylase/otc defici data first cohort treat lowest-dos
gc/kg although sampl size small shi complet data
pt pt observ week pt observ week preliminari look warrant
encourag report safe infusion-rel base
pt complet data could posit efficaci effect
immunogen ureagenesi remain seen pt mild alanin aminotransferase/alt
peak iu/l normal mainten ureagenesi week howev pt
elev alt level peak iu/l show clinic meaning chang
rate ureagenesi immunogen effect ureagenesi remain uncov
ultragenyx report granular data gene therapi develop hemophilia parallel
mp op link link link link ultragenyx plan treat second cohort
higher-dos gc/kg pend data monitor committe review
safeti data second cohort data anticip assum advanc
could effect although immun effect ureagenesi remain seen
second cohort treat higher gc/kg dose anticip data
bottom line provid updat tax reform guidanc street expect
cash tax payment expect mm lower compar street expect
mm headwind posit chang compani abil util
nol cash tax payment mm lower due repeal altern minimum tax
abil realiz nol absenc cash tax aid abil reduc
leverag previous assum would pay cash tax howev tax reform
ep headwind due chang corpor interest deduct updat adjust ep midpoint
vs previou midpoint consensu estim
activ reduc leverag partial eas corpor interest deduct headwind also
taxabl incom lower due posit impact bonu depreci tax reform
impact ebitda
materi chang abil util nol
mm cash tailwind repeal appear street estim assum greater
mm cash tax
taxabl incom lower due bonu depreci
recent announc divestitur tx mo part mm plan divestitur
guidanc conif divestitur note avail follow link
recent tax reform analysi health care facil manag care avail follow
timelin consist expect diversifi mab pipe track
bottom line announc prioriti mileston line investor expect
prior guidanc mileston includ initi phase studi
initi data phase ii studi system lupu erythematosu sle
potl initi phase data nv mp -partner bispecif antibodi
addit seek outlicens anti-ig asthma
four addl ind file ph initi proprietari bispecif antibodi on-going phase trial
run license op morphosi remain track compani remain well capit
end cash equival management expect suffici fund oper
develop track initi phase studi expect
bispecif antibodi technolog key aspect growth strategi oncolog data
continu seek develop partner
new agent early-stag proprietari pipelin disclos highlight product engin
partner program phase
 methodolog ep
bottom line decent quarter view publish updat model
account result revis guidanc even though retail usa revenu volum growth
good disappoint divis oper incom miss estim
consensu progress year believ win share
given s- rx growth guidanc provid op week market competit
continu heat believ becom even challeng deliv usa
retail oper incom beat progress maintain mp
also behind estim
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo
adjust revenu billion
sale
bottom line share react neg yesterday sooner-than-expect news abt
mp freestyl libr secur approv driven ramp investor concern
essenti implicitli view libr equival devic commerci payer
ultim pressur price forc match sensor asp
patient coverag hand libr access medicar patient
short-liv monopoli -- someth potenti remov sourc upsid
number yesterday afternoon spoke medacorp specialist -- healthcar economist
done extens work payer cgm reimburs -- assess former concern overal
convers reinforc view continu warrant least price
premium libr given alert alarm capabl presum better outcom
patient accord specialist rough-cut sensit analysi price cut
durabl sensor commerci patient also suggest deliv compound-annual-growth-rate
time-frame even absorb price cut sensor price
cut durabl price cut sensor figur increment price cut top
work assumpt price cut durabl continu recommend buy
weak particularli investor month time horizon
excel guid new ceo chairman
bottom line morn ahead confer dplo provid preliminari
guidanc re-affirm guidanc announc ceo transit plan preliminari
guidanc look good view outlook call adjust ebitda
rang compar leerink/consensu ebitda
expect upper end previous guid rang dplo
also announc board appoint jeff park interim ceo phil hagerman
retir phil hagerman remain member board serv consult
board appoint wolin chairman board effect immedi view
announc signific posit guid ahead expect new ceo
chairman increas odd sale larg enterpris view maintain op
dplo
new ceo bring zfgn back diseas game
bottom line today zfgn announc new candid prader-willi syndrom pw rare
genet disord character obes complet enrol program evalu
type diabet commentari debt financ structur fund
oper beyond view effort new ceo jefferi hatfield encourag
set posit tone
weekli im trend week end decemb
bottom line note analyz im script trend week end decemb
harvoni epclusa vosevi mp mavyret op zepati mp hcv genvoya
descovi odefsey hiv tagrisso azn mp lung cancer imbruvica abbv/jnj
op zydelig venclexta abbv/rhhbi nr hematolog malign ibranc
mp kisqali nv mp verzenio mp breast cancer xtandi zytiga
prostat cancer cabometyx mp renal cell carcinoma otezla celg op plaqu psoriasi
psoriat arthriti cosentyx nv plaqu psoriasi psoriat arthriti ankylos spondyl
taltz plaqu psoriasi dupix sni op/regn op eucrisa atop dermat
kevzara sny/regn rheumatoid arthriti tecfidera mp multipl sclerosi breo anoro
incrus gsk mp/inva nr chronic obstruct pulmonari diseas nucala gsk asthma
praluent sny/regn repatha mp entresto nv cardiovascular diseas trulic
jardianc basaglar toujeo soliqua sni tresiba xultophi nvo mp
diabet contrav orex nr obes ocaliva mp primari biliari cholang intrarosa
mp dyspareunia
pleas see bodi report detail weekli im script
encourag advanc set catalyst rich
bottom line met management morn discuss on-going progress lead
program urea cycl disorder/ucd liver cirrhosi elev ammonia
phenylketonuria/pku remain track advanc set multipl
catalyst believ could increas investor interest full data healthi volunt hv
present medic meet follow posit interim data
link data liver cirrhosi elev ammonia ucd anticip
respect pku investig new drug ind applic initi
interim data anticip cash runway fund catalyst
compani continu bolster pipelin pre-clin program reiter op
initi mp downsid risk franchis remain overhang
use discount rate termin growth rate
initi mp divers portfolio tough gener environ pt
sum-of-the-part weight average ev/ebitda multipl
initi mp get mojo back pipelin visibl limit pt
sum-of-the-part weight average ev/ebitda multipl
initi op opportun valid anti-mir therapi kidney
discount rate termin growth rate
biotech portfolio concentr explain multipl compress
dol expand associ health plan -ve facil larg cap
top question facil manag team upcom
question hcit distribut
qs med-tech life scienc tool mgmt ahead earn
risk-adjust mean sale discount net cash
exceed prior guid approv expect move
small impress aspiro data set stage valid pt
 methodolog dcf analysi discount rate termin growth rate
revisit long-lost forgotten triheptanoin updat
jan margituximab phase i/ii data gastric cancer
margetuximab evalu phase i/ii keytruda combin studi second-lin
gastric cancer enrol expect complet clinic data
expect asco-gi jan
management indic respons rate bar advanc combin
project margetuximab probability-weight breast cancer gastric cancer
sale
margetuximab ph interim futil analysi earli
tezacaftor/ivacaftor pdufa date homozyg offer improv
toler profil orkambi potenti approv offer underappreci volum
find vertex tez/iva potenti approv low-risk meaning catalyst
vertex sinc combin improv toler profil increas penetr
orkambi exist indic enabl re-treat prior discontinu
management describ tezacaftor/ivacaftor potenti approv greatest near-term driver
investor could also benefit confirm develop timelin vertex novel
tripl combin therapi begin pivot trial could result
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi four
cdtx rezafungin iv phase ii data candidemia
phase ii strive data rezafungin iv system candida infect
expect
cdtx share sold significantli earlier topic program
vulvovagin candidiasi discontinu think perceiv read-through
error continu ascrib odd approv underlin robust pharmacokinet
preclin safeti histor echinocandin data
project probability-weight rezafungin sale
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab would
attract altern cytotox standard-of-car follicular lymphoma fl
analysi commerci opportun confer augment suggest success
worth per share
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
derm phase data acn
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
project probability-adjust sale
hyperhidrosi excess sweat pdufa probability-of-
follow recent success complet futil analysi ph
studi aneurysm subarachnoid hemorrhag asah patient pivot event
edg share set in/around compani conduct interim analysi
see binari event upsid skew risk/reward
compar vs standard care oral nimodipin asah
succeed interim analysi need better oral nimodipin
base case assum odd success
project probability-weight sale
ionis-httrx phase ib data huntington diseas
ionis-httrx phase ib data earli albeit under-follow clinic event
think could offer import proof-of-principl antisens strategi huntington diseas
signific unmet medic need hd repres massiv potenti market
opportun novel disease-modifi strategi
upcom httrx result import potenti roch
also see meaning read-through op whose antisens hd program also
phase ib month behind
project ionis-httrx probability-adjust sale eu
receiv mid-teen royalti
sourc leerink research compani inform factset price prior day
fda adcom bone reproduct urolog drug
nerlynx neratinib meet ema scientif advisori group oncolog
fda adcom joint meet anesthet analges drug product
drug safeti risk manag
pdufa peg-pal phenylketonuria tezacaftor/ivacaftor cystic
fda adcom neurolog devic panel medic devic evalu clinic
data intracrani aneurysm treatment devic
pdufa akao plazomycin complic urinari tract infect bloodstream
american associ hand surgeri
plant anim genom
societi thorac surgeon
societi matern fetal medicine- pregnanc meet
american colleg radiat oncolog
societi laboratori autom screen
associ access medicin
advanc genom biolog technolog
european crohn coliti organis
advanc technolog treatment diabet
american academi dermatolog
bmt tandem meet american societi blood marrow transplant
asbmt center intern blood marrow transplant research cibmtr
societi critic medicin sccm
pittsburgh confer analyt chemistri appli spectroscopi
european congress radiolog ecr
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
 first apprais tax offer small benefit
manag insur fee moratorium meaning upsid mco
manag floor unintend consequ tax reform aet-cv
 tax cut tailwind exchang rate
hcit distribut senat approv tax reform reconcili hous
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
 aet seek creat new low-cost community-bas model
-- flash /aet may closer deal combin would creat signific
manag -- flash cvs-aet like dec per share mix
equiti question gupt ana
aet -- flash anoth rais pbm qs
 volum start show improv respond aggress
manag aet offens defens consum deal
 aet bring comprehens member
-- flash dementia psychosi btd po surpris basket high risk/
aciu kol lunch support target tau ad interim look advanc
aciu recap pipelin w/ new antibodi select cren
aciu -- flash aciu receiv chf roch phase initi anti-
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 lp hic panel controversi focu ahead data
 roll new ttr model updat spinraza pipelin pt market
 synergi specialti purchas aggress medic manag
hcit distribut outlook increasingli competit suppli chain shift
hcit distribut amazon estim matter
hcit distribut wholesal licens may start hub spoke
hcit distribut enter brick mortar space pbm deal could
hcit distribut like take modest size step pharmaci
manag entri drug distribut chain
healthcar distribut suppli chain preview price volum trend
manag -- flash marriag aet jilt altar toward
optum wanna-b
-- flash comment stir lab suppli busi back
 mix biosimilar outlook tnf without chang
 biosimilar pt ii litig delay tnf biosim remicad
controversi focu ahead drug launch
futur major invest theme backdrop clinic risk
-- flash fourier result chang standard cv patient
 fourier lift statin throne plausibl like
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma leerink confer offer first mani face offswil
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc evolut market make pivot year novo
view market perform
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic cgm libr impact market uncertain still oversold
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
hcit distribut rx distribut channel wood
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biotechnology/aan recap sma steal show migrain epilepsi pd psych
 american academi neurolog planner
 futur major invest theme backdrop
 neurosci panel takeaway leerink global
 outlook smid biotech theme rnai/antisens id
gwph qtr recap dinner physician bullish uptak ahead
gwph/aan presentation/kol event -- epidiolex profil continu look favorable/
 build solid foundat xlh data could posit ahead
gwph lower pt better data setup still solid
 own dont part wake
-- flash kol call po risk/benefit support major role orphan
 lp hic panel controversi focu ahead data
biopharma lp hic heme-onc panel point rise car-t treatment nhl
biopharma lp hic breast/ovarian cancer panel highlight pot parp
 takeaway nash panel
management dinner offer perspect pdp launch/strategi
 management dinner offer perspect pdp launch/strategi potenti
-- flash dementia psychosi btd po surpris basket high risk/
re-fil inbrija nda parkinson diseas episod believ issu
 kol dinner offer insight emerg drug psych
 recap sma steal show migrain epilepsi pd psych
 upgrad op overhang remov shot base fda/cn
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
mdco payor survey explor elast price outcom data
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
 hemophilia panel takeaway leerink global healthcar
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
 tecfidera settlement hedg downsid scenario known larg
biopharma cafc oral argument justic challeng scope ab patent
biopharma regn/sni appeal brief strong case cafc buck
 injunct offer upsid downsid
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
achn partnership termin push cfd inhibitor main stage pt
aesthet devic -- flash purchas zltq valid ni fat market
aesthet devic talk heat aesthet
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top list
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 insight jan investor dinner former aet ceo
 outperform
pthn downgrad market perform pend acquisit pt
 add cscc respons diseas boost /sni
 refin model reflect acquisit detail outperform
 updat model reflect patheon acquisit pt outperform
-- flash partner drug advanc phase outperform
 celg defend celgen could
self-help stori
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 gwph major takeaway weekend annual
epilepsi meet
 analyst event best idea
share teva tourett look better
outperform
healthcar leerink outlook
manag convers
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma us biopharma product updat lli premium us
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight breast cancer kol discuss
biopharma highlight lung cancer kol discuss
biopharma highlight asthma/copd kol discuss
biopharma highlight immuno-oncolog kol discuss
biopharma highlight myeloma kol discuss
window rival
biopharma highlight heart failur kol discuss
aldr -- flash management dinner includ discuss product differenti ip im/
-- flash takeaway investor dinner rais stori intact
biopharma io combo panel takeaway leerink global healthcar
 hemophilia panel takeaway leerink global healthcar
 neurosci panel takeaway leerink global
hcit distribut leerink confer panel highlight rx suppli chain
healthcar summari leerink global healthcar confer
medic suppli devic leerink confer panel highlight three
adap -- flash addl respons seen tcr synovi sarcoma updat
-- flash event highlight potenti sting activ
biopharma -- flash olympiad data solid gbrca breast lynparza benefit may
driven
biopharma xclips xtandi hope get stampede-d
 day takeaway data focu among emerg
-- flash bcma car-t continu outperform
-- flash event highlight data myeloma
-- flash event focus emerg target biomark strategi
 encourag earli updat outperform
cldx -- flash glemba get harsh review discuss varli nivo data
-- flash increment cotel melanoma updat asco bode
-- flash grail highlight earli ctdna data liquid biopsi start gain
imdz -- flash continu show favor os await combo data
imdz -- flash phase radiat data show abscop effect follicular
juno -- flash emerg profil dlbcl look promis pivot trial
-- flash data solid w/ manag diarrhea
-- flash highlight investor event broad keytruda
major io lung cancer highlight win battl
small dataset
 add cscc respons diseas boost /sni
-- flash updat support strong profil dev bladder
tsro -- flash topacio show encourag initi orr zejula keytruda
 mix outlook physician survey regard intrarosa
 pbc survey suggest ocaliva safeti concern manag
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
medic suppli devic survey surprisingli posit trend support
 physician survey support nerlynx opp ty breast cancer pt
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
healthcar outlook healthcar invest opportun year chang
